

Styrax camporum and *S. ferrugineus* fruits: norneolignans, antioxidant and cytotoxic activities

Thais de Almeida Silva, Evelise Martins Polo, Camila Yamasita Henrique, Osvaine Júnior Alvarenga Alves, Heloiza Diniz Nicolella, Valéria Maria Melleiro Gimenez, Alba Regina Barbosa Araújo, Denise Crispim Tavares, Márcio Luís Andrade e Silva, Wilson Roberto Cunha, Ana Helena Januário, Patricia Mendonça Pauletti*

Center for Research in Exact and Technological Sciences, University of Franca, Franca, Brazil.

ARTICLE INFO

Article history:

Received on: 12/08/2016

Revised on: 03/10/2016

Accepted on: 24/10/2016

Available online: 29/11/2016

Key words:

Styrax camporum; *Styrax ferrugineus*, DPPH, cytotoxicity.

ABSTRACT

The present study evaluated the antioxidant and cytotoxic activities of the methanol extract of *Styrax camporum* and *S. ferrugineus* fruits. Purification of both extracts, which displayed weak antioxidant and cytotoxic activities, resulted in isolation of seven compounds: homoeogonol (**1**), egonol (**2**), demethoxy egonol-2-methylbutanoate (**3**), egonol gentiobioside (**4**), demethoxy egonol (**5**), demethoxy homoeogonol (**6**), and egonol-2-methylbutanoate (**7**). XTT cell culture and DDPH assays helped to assess the activity of the pure compounds. Compared to gallic acid at 66.7 µg/mL, the evaluated norneolignans were inactive in the DPPH assay. The cytotoxicity assay revealed that egonol acetate and compound **3** had CC₅₀ of 267.90 and 19.10 µg/mL at 24 h. Compound **3** was also assayed on cancer cells lines (HeLa, MO59J and MCF-7), but it did not reduce the viability of these cells with the same efficiency. Again, the results presented here confirmed that the egonol core is a promising structural feature for anticancer drug research.

INTRODUCTION

A diet that advocates fruits intake has long been recognized as an ally in promoting health and preventing disease. Such diet reduces the risk of chronic diseases such as cancer, diabetes, cardiovascular disease, and arthritis. Indeed, fruits are normally rich in antioxidants, like tannins, stilbenes, flavonoids, and phenolic acids (Kozłowska and Szostak-Wegierek, 2014; Zhang *et al.*, 2015). Several fruits with high potential for agriculture are native to the Brazilian cerrado. Local people have traditionally consumed these fruits, which display high nutritional and economic potential (Siqueira *et al.*, 2013; Agostini-Costa *et al.*, 2006). In fact, the nutritional value of these fruits has led to their increasing consumption nationwide and worldwide (Rufino *et al.*, 2010). In addition, these fruits present high antioxidant capacity and prominent phenolic content

(Cândido *et al.*, 2015; Siqueira *et al.*, 2013; Rocha *et al.*, 2011; Silva *et al.*, 2008). *Styrax camporum* Pohl and *Styrax ferrugineus* Ness et. Mart. are two species that occur in the Brazilian cerrado. However, no research on the chemical and biological potential of their fruits has been conducted. Existing studies on *S. camporum* and *S. ferrugineus* have been limited to their leaves and barks (Francielli de Oliveira *et al.*, 2012; Braguine *et al.*, 2012; Teles *et al.*, 2005; Bacchi and Sertié, 1995; Pauletti *et al.*, 2000). In indigenous medicine, *S. camporum* and *S. ferrugineus* have been employed in the treatment of gastrointestinal diseases and fever, respectively (Lorenzi, 1982; Rodrigues and Carvalho, 2008). The two species produce a resinous material that is secreted when the barks and trunks are injured by sharp objects, and this material can be used in place of benzoin resin, which presents anti-inflammatory actions (Silva-Júnior and Pereira, 2009; de Almeida *et al.*, 1998). Additionally, the fruits of *S. ferrugineus* are used in homemade jams (Silva-Júnior, 2012). Furthermore, the fruits of *S. camporum* feed also the wild animals, and have slightly sweet taste (Silva-Junior and Pereira, 2009; Kuhlmann 2012).

* Corresponding Author
E-mail: patrpaul@gmail.com

Recently, LC-MS analysis of the fruits of *S. ramirezii*, from Mexico, accomplished by Timmers *et al.* (2015) has enabled their chemical characterization and determination of their antioxidant and anti-inflammatory activities. These authors also evaluated the compounds isolated from these fruits, egonol and homoegonol, in the bioassays. The results suggested that the inclusion of *S. ramirezii* fruits in the diet contributes with antioxidant and anti-inflammatory compounds intake.

Considering the need to understand native fruits better, we have assayed the methanol crude extract of *Styrax camporum* and *S. ferrugineus* fruits in the presence of DPPH (2,2-diphenyl-1-picrylhydrazyl) and evaluated their cytotoxicity. We have also investigated the chemical composition and antioxidant and cytotoxicity properties of the isolated compounds.

MATERIAL AND METHODS

General

^1H and ^{13}C NMR spectra were recorded in CDCl_3 or $\text{DMSO}-d_6$ on a Bruker AVANCE DRX 500 or on a Bruker DPX-400 spectrometer (Bruker Corporation, USA); TMS was used as internal standard. HPLC was accomplished on a Shimadzu LC-6AD system (Kyoto, Japan) equipped with a DGU-20A5 degasser, an SPD-20A series UV-VIS detector or an SPDM-20A series PDA detector, a CBM-20A communication bus module, a Reodyne manual injector, and LCsolution software. The columns and pre-columns were SHIMADZU Shim-pack ODS (particle diameter 5 μm , 250 x 4.60 mm, and 250 x 20 mm). The MeOH employed in the analyses was HPLC grade, J. T. Baker. Direct-Q UV3 system, Millipore was used to obtain ultrapure water. Silica gel 60 (230-400 mesh, Sigma-Aldrich) was employed for column chromatography, and silica on TLC Al foils with fluorescent indicator 254 nm (Sigma-Aldrich) was also used. Prep-TLC was conducted on silica gel type G (Sigma-Aldrich).

Fruit Material

The fruits of *Styrax camporum* Pohl were collected at the campus of the University of São Paulo, Pirassununga, SP, Brazil, in February 2013, and the fruits of *S. ferrugineus* Ness et. Mart. were collected at Santa Cecilia, Patrocínio Paulista, SP, Brazil, in October 2012. The materials were identified by Prof. V.M.M. Gimenez and Prof. A.R.B. Araújo. Voucher specimens (SPFR 12170 and SPFR 12169, respectively) were deposited in the Herbarium of the Department of Biology, Faculdade de Filosofia Ciências e Letras de Ribeirão Preto, University of São Paulo, Brazil (Herbarium SPFR).

Extraction and isolation

The air-dried, powdered fruits (94.7 g) of *S. ferrugineus* were extracted with AcOEt, and then with MeOH, yielding 8.8 and 8.6 g of crude extract, respectively. The solvents were selected based on previous work (Liu *et al.*, 2011). The crude MeOH extract (MESF, 3.5 g) was fractionated on a column

chromatography on silica gel using a gradient of *n*-hexane/EtOAc as eluent, which afforded 66 fractions. In a previous study, our research group had purified the fractions 19-30 and 32-36 and obtained compounds **1** and **2** (de Oliveira *et al.*, 2016). Fractions 12-13 yielded compound **3** (12.9 mg) after Prep-TLC using *n*-hexane-EtOAc (9:1, v/v) as the mobile phase. Fraction 65 was purified by Prep-HPLC using MeOH/H₂O (60:40, v/v) as mobile phase, UV detection at 254 nm, and 8 mL/min flow rate were used, to yield five fractions. Fraction 3 gave compound **4** (54.8 mg, t_{R} 43.9 min).

The air-dried, powdered fruits (63 g) of *S. camporum* were extracted with MeOH, yielding 13.3 g of crude extract. The crude MeOH extract (MESF, 5 g) was fractionated on a column chromatography on silica gel (70–230 mesh) by using a gradient of *n*-hexane/EtOAc as eluent, which afforded 59 fractions. Fractions 26-29, 30-32 and 43-46 furnished compounds **5**, **1** and **2**, respectively.

Fractions 33-39 were purified by using Prep-HPLC with MeOH/H₂O (80:20, v/v) as eluent, UV detection at 254 nm, and 8 mL/min flow rate, to yield three fractions. Fraction 2 gave compound **6** (10 mg, t_{R} 13.1 min). Fractions 13-19 were purified by using Prep-HPLC with MeOH/H₂O (85:15, v/v) as eluent, UV detection at 254 nm, and 8 mL/min flow rate, to yield nine fractions. Fraction 6 gave compound **7** (10.3 mg, t_{R} 36.7 min).

Homoegonol (1).

^1H -NMR (CDCl_3 , 500 MHz): δ 7.46 (1H, dd, J = 8.2 and 1.8, H-6'), 7.37 (1H, d, J = 1.8, H-2'), 6.98 (1H, br s, H-4), 6.93 (1H, d, J = 8.2, H-5'), 6.84 (1H, s, H-3), 6.64 (1H, br s, H-6), 4.04 (3H, s, 7-OCH₃), 3.99 (3H, s, 4'-OCH₃) 3.93 (3H, s, 3'-OCH₃), 3.71 (2H, t, J = 6.0, H-3''), 2.79 t (2H, J = 7.9, H-1''), 1.96 (2H, m, H-2'').

Egonol (2).

^1H -NMR (CDCl_3 , 500 MHz): δ 7.40 (1H, dd, J = 8.0 and 1.7, H-6'), 7.32 (1H, d, J = 1.7, H-2'), 6.97 (1H, d, J = 1.3, H-4), 6.87 (1H, d, J = 8.0, H-5'), 6.79 (1H, s, H-3), 6.63 (1H, d, J = 1.3, H-6), 6.01 (2H, s, OCH₂O), 4.03 (3H, s, 7-OCH₃), 3.71 (2H, t, J = 6.3, H-3''), 2.78 (2H, t, J = 7.5, H-1''), 1.94 (2H, m, H-2'').

7-Demethoxy egonol-2-methylbutanoate (3).

^1H -NMR (CDCl_3 , 500 MHz): δ 7.32 (1H, d, J = 8.2, H-7), 7.30 (1H, dd, J = 8.0 and 1.7, H-6'), 7.26 (1H, d, J = 1.3, H-4), 7.23 (1H, d, J = 1.7, H-2'), 7.00 (1H, dd, J = 8.2 and 1.3, H-6), 6.81 (1H, d, J = 8.0, H-5'), 6.73 (1H, s, H-3), 5.94 (2H, s, OCH₂O), 4.04 (2H, t, J = 6.0, H-3''), 2.70 (2H, t, J = 7.9, H-1''), 2.30 (1H, m, H-2a), 1.92 (2H, m, H-2''), 1.61 (1H, m, H-3a), 1.41 (1H, m, H-3a), 1.07 (3H, d, J = 7.0, H-5a), 0.83 (3H, t, J = 7.4, H-4a). ^{13}C NMR (100 MHz, CDCl_3): δ 176.8 (C=O, C-1a), 156.0 (C-2), 153.4 (C-8), 148.1 (C-4'), 148.0 (C-3'), 135.9 (C-5), 129.5 (C-9), 124.8 (C-1'), 124.5 (C-6), 120.0 (C-4), 119.1 (C-6'), 110.7 (C-7), 108.7 (C-5'), 105.4 d (C-2'), 101.3 (OCH₂O), 100.0 (C-3), 63.5 (C-3''), 41.1

(C-2a), 32.1 (C-1''), 30.9 (C-2''), 26.8 (C-3a), 16.7 (C-5a), 11.7 (C-4a).

Egonol gentiobioside (4).

¹H-NMR (DMSO-*d*₆, 500 MHz): δ 7.40 (1H, dd, *J* = 8.0 and 1.5, H-6'), 7.43 d (1H, d, *J* = 1.5, H-2'), 7.00 (1H, br s, H-4), 7.21 (1H, s, H-3), 7.03 (1H, d, *J* = 8.0, H-5'), 6.78 (1H, br s, H-6), 6.09 (2H, s, OCH₂O), 4.21 (1H, d, *J* = 7.5, H-1'''), 4.12 (1H, d, *J* = 7.9, H-1''), 3.94 (3H, s, 7-OCH₃), 3.92 (1H, d, *J* = 10.4, H-6'''), 3.79 (1H, m, H-3''), 3.68 (1H, dd, *J* = 11.2 and 5.3, H-6'''), 3.54 (1H, dd, *J* = 10.4 and 6.4, H-6'''), 3.43 (1H, m, H-3''), 3.27 (2H, m, H-4'''' and H-5'''), 3.14 (2H, t, *J* = 8.5, H-5'''' and H-3'''''), 3.08 (2H, t, *J* = 8.5, H-3'''' and H-4'''''), 2.98 (3H, m, H-6''''', H-2'''' and H-2'''''), 2.72 (2H, m, H-1'''), 1.86 (2H, m, H-2'''). ¹³C NMR (125 MHz, DMSO-*d*₆): δ 156.0 (C-2), 149.0 (C-4'), 148.0 (C-3'), 145.2 (C-7), 142.0 (C-8), 138.0 (C-5), 131.0 (C-9), 125.0 (C-1'), 119.6 (C-6'), 113.0 (C-4), 109.7 (C-5'), 108.7 (C-6), 105.8 (C-2'), 104.9 (C-1'''), 103.7 (C-1''), 102.3 (OCH₂O), 102.0 (C-3), 77.5 (C-3''', C-5'''' and C-3'''''), 76.6 (C-5'''''), 74.2 (C-2'''' and C-2'''''), 70.8 (C-4'''), 70.5 (C-4'''''), 69.2 (C-6'''''), 68.7 (C-3'''), 66.5 (C-6'''''), 56.6 (7-OCH₃) 32.7 (C-1''), 32.3 (C-2'').

Demethoxy egonol (5).

¹H-NMR (CDCl₃, 500 MHz): δ 7.37 (1H, d, *J* = 8.0, H-7), 7.35 (1H, d, *J* = 8.0, H-5'), 7.34 (1H, d, *J* = 1.6, H-4), 7.28 (1H, d, *J* = 1.6, H-2'), 7.07 (1H, br d, *J* = 8.0, H-6), 6.86 (1H, dd, *J* = 8.0 and 1.6, H-6'), 6.77 (1H, s, H-3), 5.98 (2H, s, OCH₂O), 3.66 (2H, t, *J* = 6.2, H-3''), 2.77 (2H, t, *J* = 7.2, H-1''), 1.91 (2H, m, H-2''). ¹³C NMR (100 MHz, CDCl₃): δ 155.9 (C-2), 153.3 (C-8), 148.1 (C-3'), 148.0 (C-4'), 136.4 (C-5), 129.5 (C-9), 124.8 (C-1'), 124.6 (C-6), 120.0 (C-4), 119.0 (C-5'), 110.7 (C-7), 108.6 (C-6'), 105.4 (C-2'), 101.3 (O-CH₂-O), 100.0 (C-3), 62.1 (C-3''), 34.7 (C-2''), 31.9 (C-1'').

Demethoxy homoegonol (6).

¹H-NMR (CDCl₃, 500 MHz): δ 7.41 (1H, dl, *J* = 8.0, H-6), 7.41 (1H, br d, *J* = 8.0, H-6'), 7.36 (1H, br s, H-4), 7.36 (1H, br s, H-2'), 7.10 (1H, d, *J* = 8.0, H-7), 6.93 (1H, d, *J* = 8.0, H-5'), 6.85 (1H, s, H-3), 3.99 (3H, s, 4'-OCH₃), 3.93 (3H, s, 3'-OCH₃), 3.70 (2H, t, *J* = 6.2, H-3''), 2.80 (2H, t, *J* = 7.5, H-1''), 1.94 (2H, m, H-2''). ¹³C NMR (100 MHz, CDCl₃): δ 156.0 (C-2), 153.4 (C-8), 149.5 (C-4'), 149.1 (C-3'), 136.4 (C-5), 129.6 (C-9), 124.6 (C-1'), 124.5 (C-6), 119.9 (C-4), 117.9 (C-6'), 111.3 (C-5'), 110.7 (C-7), 107.9 (C-2'), 99.8 (C-3), 62.3 (C-3''), 56.0 (O-CH₃), 34.7 (C-1''), 32.0 (C-2'').

Egonol-2-methylbutanoate (7).

¹H-NMR (CDCl₃, 400 MHz): δ 7.40 (1H, dd, *J* = 8.0 and 2.0, H-6'), 7.32 (1H, d, *J* = 2.0, H-2'), 6.95 (1H, d, *J* = 1.7, H-4), 6.87 (1H, d, *J* = 8.0, H-5'), 6.79 (1H, s, H-3), 6.60 (1H, d, *J* = 1.7, H-6), 6.00 (2H, s, OCH₂O), 4.12 (2H, t, *J* = 6.7, H-3''), 4.03 (3H, s, 7-OCH₃), 2.75 (2H, t, *J* = 7.9, H-1''), 2.39 (1H, m, H-2a), 1.98 (2H, m, H-2''), 1.68 m (1H, m, H-3a), 1.49 (1H, m, H-3a), 1.16 (3H, d, *J* = 7.0, H-5a), 0.92 (3H, t, *J* = 7.3, H-4a).

Acetylation of (1) and (2)

Homogonol (1) and egonol (2) (5 mg) were dissolved in acetic anhydride (3 mL) and pyridine (3 mL). The mixture was allowed to react overnight. Then, cold H₂O (30 mL) was added, and the mixture was extracted with CH₂Cl₂ (2 x 15 mL), HCl 10% (2 x 15 mL), and H₂O (3 x 15 mL). Anhydrous sodium carbonate was added on to the organic phase, which was then filtered and concentrated under reduced pressure, to yield acetate derivatives **1a** and **2a**.

Homoegonol acetate (1a).

¹H-NMR (CDCl₃, 500 MHz): δ 7.46 (1H, dd, *J* = 2.0 and 8.4, H-6'), 7.37 (1H, d, *J* = 2.0, H-2'), 6.97 (1H, d, *J* = 1.2, H-4), 6.93 (1H, d, *J* = 8.4, H-5'), 6.84 s (1H, s, H-3), 6.61 (1H, d, *J* = 1.2, H-6), 4.13 (2H, t, *J* = 7.8, H-3''), 4.03 (3H, s, 7-OCH₃), 3.93 (3H, s, 4'-OCH₃), 3.83 (3H, s, 3'-OCH₃), 2.76 (2H, t, *J* = 7.5, H-1''), 2.07 (3H, s, 3''-COOCH₃), 2.01 (2H, m, H-2'').

Egonol acetate (2a).

¹H-NMR (CDCl₃, 500 MHz): δ 7.40 (1H, dd, *J* = 1.6 and 8.2, H-6'), 7.32 (1H, d, *J* = 1.6, H-2'), 6.96 (1H, d, *J* = 1.1, H-4), 6.87 (1H, d, *J* = 8.2, H-5'), 6.79 (1H, s, H-3), 6.61 (1H, d, *J* = 1.1, H-6), 6.01 (2H, s, OCH₂O), 4.12 (2H, t, *J* = 6.5, H-3''), 4.01 (3H, s, 7-OCH₃), 2.75 (2H, t, *J* = 7.7, H-1''), 2.00 (2H, m, H-2''), 2.07 (3H, s, 3''-COOCH₃).

Cytotoxicity Assay

The cytotoxicity of the extracts (MESF and MESC) and compounds (**1a**, **2a**, **3**, **4**, **5**, **6** and **7**) was first assessed in the case of cell line GM07492A (normal human lung fibroblasts). Then, compound **3** was tested in the case of the cancer cell lines: human breast adenocarcinoma (MCF-7), human cervical adenocarcinoma (HeLa), and human glioblastoma (MO59J). The cell lines were maintained as monolayers in plastic culture flasks (25 cm²) containing HAM-F10 plus DMEM (1:1; Sigma-Aldrich), with 10% fetal bovine serum (Nutricell), 2.38 mg/mL Hepes (Sigma-Aldrich), 0.01 mg/mL streptomycin (Sigma-Aldrich), and 0.005 mg/mL penicillin (Sigma-Aldrich), at 37°C and under humidified atmosphere with 5% CO₂. Cells from the fourth to the twelfth passage were used.

Cytotoxicity was measured by using the Colorimetric Assay *In Vitro* Toxicology, XTT Kit (Roche Diagnostics). Briefly, 1 x 10⁴ cells were seeded in microplates containing 100 µL of culture medium (1:1 HAM F10 + DMEM or DMEM alone) supplemented with 10% fetal bovine serum and concentrations of the tested extracts and compounds ranging from 1.25 to 2500 µg/mL. Negative (no treatment), solvent (0.02% DMSO) and positive (25% DMSO) controls were added to the microplate. After incubation at 36.5 °C for 24 h, the culture medium was removed and the cells were washed with 100 µL of PBS. Next, 100 µL of culture medium HAM-F10 without phenol red was added. Then, 25 µL of XTT were plated and incubated at 36.5 °C for 17 h. The absorbance of the wells was determined at a wavelength of 450 nm and a reference length of 620 nm by using a

multi-plate reader (ELISA - Tecan - SW Magellan vs 5.03 STD 2P).

Antioxidant activity

The antioxidant activity of crude extracts (MESF and MESC) and compounds was determined by using DPPH (2,2-diphenyl-1-picrylhydrazyl). DPPH (26.7 µg/mL) dissolved in MeOH was added to the samples containing concentrations of the tested extracts/compounds ranging from 66.7 -1.67 µg/mL in MeOH. The mixture were incubated at room temperature, in the dark, for 30 min. Remaining DPPH was determined at 517 nm in a microplate reader. The antioxidant activity was expressed by using values obtained as percent of scavenging calculated from the equation: % of scavenging= $(A_{DPPH} - A_{sample} / A_{DPPH}) * 100$, where A_{DPPH} is the absorbance of the solution with DPPH only, and A_{sample} is the absorbance of the solution with extracts and compounds.

Statistical analyses

All the experiments were performed in triplicate, and the results are presented as the mean ± SD. The cytotoxicity effect was established based on the CC_{50} response parameter (cytotoxic concentration values that cause 50% cell growth inhibition for the different cell lines after 24h of observation) calculated with the GraphPad Prism program. One-way analysis of variance (ANOVA) was used to compare the differences between the means; significance was set at $p < 0.05$.

RESULTS AND DISCUSSION

Free radicals are recognized as key intermediaries in several diseases like diabetes mellitus, cancer, liver diseases, renal failure, and degenerative diseases, caused by a deficient natural antioxidant protection mechanism. Thus, researches for beneficial bioactivities from plants are considered to be a rational approach

in drug development (Roy *et al.*, 2016). Additionally, fruits are known as super antioxidants and cancer protective agents, fruits are gaining attention for the exploration of their health improvement properties (Lim *et al.*, 2007; Saini *et al.*, 2014).

In this way, to establish the potential of the methanol crude extracts of *S. ferrugineus* (MESF) and of *S. camporum* (MESC) fruits, we screened the extracts for their antioxidant and cytotoxic activity *in vitro* (Table 1). The DPPH assay was selected due to its low-cost and easiness, and therefore has been used for the initial evaluation of the fruits extracts and isolated compounds antioxidant properties (Apak *et al.*, 2016). The percentage of DPPH scavenging was 18.47 and 2.40 at 66.7 µg/mL for MESC and MESF, respectively. MESC afforded better antioxidant results as compared to MESF. Regarding the DPPH assay, the values obtained for the extracts were considered weak as compared to the positive control, gallic acid. This result could be explained in terms of the extraction procedure: we did not use acidified methanol to extract the polyphenol compounds (Timmers *et al.*, 2015). In order to study the toxicological properties of the extracts we investigated the cytotoxicity on normal human lung fibroblast cells (GM07492A). The CC_{50} of MESC and MESF obtained in the assay was 270.8 and 164.7 µg/mL, respectively. According to Suffness and Pezzuto (1990), only CC_{50} lower than 30 µg/mL indicates cytotoxic action. Hence, neither of the tested extracts displayed cytotoxicity, but MESF was more active than the MESC.

Purification of MESF and MESC led to the isolation of seven compounds (Figure 1): homoegonol (1), egonol (2), demethoxy egonol-2-methylbutanoate (3), egonol gentiobioside (4), demethoxy egonol (5), demethoxy homoegonol (6), and egonol-2-methylbutanoate (7). NMR spectroscopy helped to establish their chemical structures, which agreed with published data (Segal *et al.*, 1967; Pauletti *et al.*, 2000; Akgul and Anil, 2003; Takanashi *et al.*, 1974; Lee *et al.*, 2008; Takanashi and Takizawa, 2002; Takanashi and Takizawa, 1988).

Table 1: Antioxidant and cytotoxic activities of the extracts and *normeolignans* evaluated herein.

Samples	DPPH % inhibition	GM07492A	CC ₅₀ (µg/mL)		
			Cell lines		
			HeLa	MO59J	MCF-7
MESC	18.47 ± 1.54 ^{ab}	270.8 ± 14.2 ^a	-	-	-
MESF	2.40 ± 2.01 ^b	164.7 ± 10.9 ^c	-	-	-
1a	n. a.	1069.6 ± 35.1 ^{ac}	-	-	-
2a	4.93 ± 0.99 ^b	267.9 ± 1.9 ^a	-	-	-
3	n. a.	19.10 ± 0.75 ^{ac}	1739.7 ± 327	> 2500	1411.7 ± 240.6
4	2.90 ± 1.83 ^b	> 2500 ^{ac}	-	-	-
5	5.04 ± 2.19 ^b	1897.7 ± 56.3 ^{ac}	-	-	-
6	n. a.	842.6 ± 31.2 ^{ac}	-	-	-
7	4.28 ± 0.92 ^b	> 2500 ^{ac}	-	-	-
Gallic acid	92.41 ± 0.34 ^b	-	-	-	-
Doxorubicin	-	7.8 ± 0.9 ^{ac}	21.9 ± 9.1	6.9 ± 2.1	5.4 ± 1.3

The values are the mean ± SD, n=3.

DPPH (2,2-diphenyl-1-picrylhydrazyl).

CC₅₀ 50% cytotoxic concentration values for the different cell lines after 24-h treatment.

GM07492A (Human lung fibroblasts), MCF-7 (human breast adenocarcinoma), MO59J (human glioblastoma) and HeLa (human cervical adenocarcinoma).

^a Significantly different from treatment with MESF ($p < 0.001$).

^b Significantly different from treatment with gallic acid ($p < 0.001$).

^c Significantly different from treatment with MESC ($p < 0.001$).




Fig. 1: Chemical structures of *norneolignans*.

Table 1 compiles the results achieved during the antioxidant assay of the isolated compounds. The evaluated *norneolignans* were inactive as compared to gallic acid at 66.7 µg/mL. According to the literature (Hou *et al.*, 2003), the presence of compounds with stronger proton-donating capacity, such as phenolic compounds, is correlated to the DPPH scavenging activity. Based on our results, the compounds tested herein were almost inactive. The isolated compounds did not display free hydroxyl groups, so, the *norneolignans* contributed to the extracts weak antioxidant activities.

To ascertain the toxicological properties of the assessed compounds, we conducted a 24-h XTT trial on normal human lung fibroblast cells (GM07492-A). Table 1 outlines the CC₅₀ values. Treatment of the normal cells with compounds **1a**, **4**, **5**, **6** and **7** did not reduce cell viability significantly. These compounds were even less active than the MESF and MESF; e.g., compound **2a** yielded CC₅₀ of 267.90 µg/mL, which showed it was less active than MESF.

Compound **3** had CC₅₀ of 19.10 µg/mL, giving the most promising CC₅₀ among the evaluated *norneolignans*. To test the anticarcinogenic potential we used three cancer cell lines derived from different cancer types, human cervical adenocarcinoma (HeLa), human glioblastoma (MO59J), and human breast adenocarcinoma MCF-7 cells. For this reason, compound **3** was assayed on HeLa, MO59J, and MCF-7 cells, without effective reduction in cell viability.

The most active compounds (**2a** and **3**) have quite similar chemical structure: both bear an egonol core. The difference

between their structures lies on the presence of acetate at R¹ in compound **2a**, whereas 2-methylbutanoate exists at R¹ and the methoxyl group at C-7 is absent in compound **3**. De Oliveira *et al.* (2016) had already evaluated the action of homoegonol (**1**) and egonol (**2**) on normal human cell (GM07492A), murine melanoma (B16F10), human cervical adenocarcinoma (HeLa), human hepatocellular liver carcinoma (HepG2), human breast adenocarcinoma (MCF-7), and human glioblastoma (MO59J). The authors established that a combination of compounds **1** and **2** and compound **2** alone exhibited CC₅₀ values lower than 30 µg/mL for MCF-7 and for HepG2 at 72 h, respectively; selectivity indices were high.

Therefore, these authors suggested that the combination of compounds **1** and **2** as well as compound **2** alone should be a promising alternative for the development of anticancer drugs. In another study that used Kato III cells to evaluate drug cytotoxicity, egonol and demethoxy egonol presented *in vitro* cytotoxicity with IC₅₀ values of 28.8 and 27.5 µg/ml, respectively (Yoshikawa *et al.*, 2001). These results again confirmed that the egonol core is a promising structural feature for anticancer drug research. According to Reiter *et al.* (2014), hybrids synthesized with egonol possess improved cytotoxic properties, thereby confirming the potential of the egonol structure in cancer research.

CONCLUSION

This is the first reported study on biological activities of fruits from *S. camporum* and *S. ferrugineus*. The present study provided evidence that the methanol extracts of *S. camporum* and *S. ferrugineus* fruits display weak antioxidant activity (18.47 %, and 2.40 % at 66.7 µg/mL), as compared with the gallic acid at this same concentration. These results stemmed from the fact that the structure of the *norneolignans* present in these extracts do not bear a phenolic group. The extracts do not display cytotoxicity, either. The exception is compound **3**, which proved to be cytotoxic to normal cells. However, compound **3** is not cytotoxic to evaluated cancer cells. The isolated *norneolignans* could be used as starting material for synthesizing more cytotoxic compounds.

ACKNOWLEDGEMENTS

Financial support and sponsorship: The authors are grateful to the São Paulo Research Foundation (FAPESP) (Grant # 2013/06164-5 and 2013/09280-6), Coordenadoria de Aperfeiçoamento de Pessoal do Ensino Superior (CAPES), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for fellowships.

Conflict of Interests: There are no conflicts of interest.

REFERENCES

Agostini-Costa TdaS, da Silva DJ, Vieira RF, Sano SM. 2006. Espécies de maior relevância para a região Centro-Oeste. In: Vieira RF, Costa TSA, da Silva DB, Ferreira FR, Sano SM, ed. Frutas nativas da

região Centro-Oeste. Brasília: Embrapa Recursos Genéticos e Biotecnologia 12-24.

Akgul YY, Anil H. Benzofurans and another constituent from seeds of *Styrax officinalis*. *Phytochemistry*, 2003; 63:939-943.

Apak R, Özyürek M, Güçlü K, Çapanoğlu E. Antioxidant Activity/Capacity Measurement. 2. Hydrogen Atom Transfer (HAT)-Based, Mixed-Mode (Electron Transfer (ET)/HAT), and Lipid Peroxidation Assays. *J Agric Food Chem*, 2016; 64:1028-1045.

Bacchi EM, Sertié JA, Villa N, Katz H. Antiulcer action and toxicity of *Styrax camporum* and *Caesalpinia ferrea*. *Planta Med*, 1995; 61:204-207.

Braguine CG, Bertanha CS, Gonçalves UO, Magalhães LG, Rodrigues V, Melleiro Gimenez VM, Groppo M, Silva ML, Cunha WR, Januário AH, Pauletti PM. 2012. Schistosomicidal evaluation of flavonoids from two species of *Styrax* against *Schistosoma mansoni* adult worms. *Pharm Biol*, 50:925-929.

Cândido TL, Silva MR, Agostini-Costa TS. Bioactive compounds and antioxidant capacity of buriti (*Mauritia flexuosa* L.f.) from the Cerrado and Amazon biomes. *Food Chem*, 2015; 177:313-319.

de Almeida SP, Proença CEB, Sano SM, Ribeiro JF. 1998. Cerrado espécies vegetais úteis. Planaltina: Embrapa Recursos Genéticos e Biotecnologia.

de Oliveira PF, Damasceno JL, Bertanha CS, Araújo AR, Pauletti, PM, Tavares, DC. Study of the cytotoxic activity of *Styrax camporum* extract and its chemical markers, egonol and homoeconol. *Cytotechnology*, 2016; 68:1597-1602.

Francielli de Oliveira P, Furtado RA, Acésio NO, Leandro LF, Montanheiro G, de Pádua FC, Corrêa MB, Braguini CG, Pauletti PM, Tavares DC. *In vivo* protective activity of *Styrax camporum* hydroalcoholic extract against genotoxicity induced by doxorubicin and methyl methanesulfonate in the micronucleus and comet assays. *Planta Med*, 2012; 78:1899-1905.

Hou WC, Lin RD, Cheng KT, Hung YT, Cho CH, Chen CH, Hwang SY, Lee MH. Free radical-scavenging activity of Taiwanese native plants. *Phytomedicine*, 2003; 10:170-175.

Lee H-J, Park S-Y, Park S-Y, Lee OK, Jo HJ, Kang H-Y, Choi D-H, Paik K-H, Khan M. Benzofurans and sterol from the seeds of *Styrax obassia*. *Chem Nat Compd*, 2008; 44:435-439.

Kozłowska A, Szostak-Węgierek D. Flavonoids-food sources and health benefits. *Rocz Panstw Zakl Hig*, 2014; 65:79-85.

Kuhlmann M. 2012. Frutos e sementes do Cerrado atrativos para fauna: guia de campo. Brasília: Ed. Rede de sementes do Cerrado.

Lim YY, Lim TT, Tee JJ. Antioxidant properties of several tropical fruits: a comparative study. *Food Chem*, 2007; 103:1003-1008.

Liu J, Dumontet V, Simonin AL, Iorga BI, Guerinéau V, Litaudon M, Nguyen VH, Gueritte F. Benzofurans from *Styrax agrestis* as acetylcholinesterase inhibitors: structure-activity relationships and molecular modeling studies. *J Nat Prod*, 2011; 74:2081-2088.

Lorenzi H. 1982. Árvores Brasileiras. Manual de identificação e cultivo de plantas arbóreas nativas do Brasil. São Paulo: Instituto Plantarum de Estudos da Flora.

Pauletti PM, Araújo AR, Young MCM, Giesbrecht AM, Bolzani VS. *nor*-Lignans from the leaves of *Styrax ferrugineus* (Styracaceae) with antibacterial and antifungal activity. *Phytochemistry*, 2000; 55:597-601.

Reiter C, Capci Karagöz A, Fröhlich T, Klein V, Zeino M, Viertel K, Held J, Mordmüller B, Emirdağ Öztürk S, Anil H, Efferth T, Tsogoeva SB. Synthesis and study of cytotoxic activity of 1,2,4-trioxane- and egonol-derived hybrid molecules against *Plasmodium falciparum* and multidrug-resistant human leukemia cells. *Eur J Med Chem*, 2014; 75:403-412.

Rocha WS, Lopes RM, da Silva DB, Vieira RF, da Silva JP, Agostini-Costa TdaS. Compostos fenólicos totais e taninos condensados em frutas nativas do Cerrado. *Rev Bras Frutic*, 2011; 33:1215-1221.

Rodrigues VEG, de Carvalho DA. Florística de plantas medicinais nativas de remanescentes de floresta estacional semidecidual na região do alto Rio Grande, Minas Gerais. *Cerne*, 2008; 14:93-112.

Roy S, Pawar S, Chowdhary A. Evaluation of *In Vitro* Cytotoxic and Antioxidant Activity of *Datura metel* Linn. and *Cynodon dactylon* Linn. Extracts. *Pharmacognosy Res*, 2016; 8:123-127.

Rufino MSM, Alves RE, Brito ES, Pérez-Jiménez J, Saura-Calixto F, Mancini-Filho J. Bioactive compounds and antioxidant capacities of 18 non-traditional tropical fruits from Brazil. *Food Chem*, 2010; 121:996-1002.

Saini R, Dangwal K, Singh H, Garg V. Antioxidant and antiproliferative activities of phenolics isolated from fruits of Himalayan yellow raspberry (*Rubus ellipticus*). *J Food Sci Technol*, 2014; 51:3369-3375.

Segal R, Milo-Goldzweig I, Sokoloff S, Zaitschek DV. A new benzofuran from the seeds of *Styrax officinalis* L. *J Chem Soc C*, 1967; 1967:2402-2404.

Silva-Júnior, MC da. 2012. 100 Árvores do Cerrado Sentido Restrito. Brasília: Ed. Rede de sementes do Cerrado.

Silva-Júnior, MC da, Pereira, BAdA. 2009. Mais 100 árvores do Cerrado. Matas de galeria. Guia de campo. Brasília: Ed. Rede de sementes do Cerrado, 110.

Silva MR, Lacerda DBCL, Santos GG, Martins DMO. Chemical characterization of native species of fruits from savanna ecosystem. *Cienc Rural*, 2008; 38:1790-1793.

Siqueira EMdA, Rosa FR, Fustinoni AM, de Sant'Ana LP, Arruda SF. Brazilian savanna fruits contain higher bioactive compounds content and higher antioxidant activity relative to the conventional red delicious apple. *PLoS One*, 2013; 8:e72826.

Suffness M, Pezzuto JM. 1990. Assays related to cancer drug discovery. In: Hostettmann K, ed. *Methods in Plant Biochemistry: Assays for Bioactivity*. London: Academic Press 71-133.

Takanashi M, Takizawa Y. New benzofurans related to egonol from immature seeds of *Styrax obassia*. *Phytochemistry*, 1988; 27:1224-1226.

Takanashi M, Takizawa Y. Isolation of new egonol compounds from seeds of *Styrax japonica* Sieb. *Et Zucc. J Oleo Sci*, 2002; 51:151-155.

Takanashi M, Takizawa Y, Mitsuhashi T. 5-(3-Hydroxypropyl)-2-(3',4' methylenedioxyphenyl)benzofuran. New benzofuran from *Styrax obassia*. *Chem Lett*, 1974; 8:869-871.

Teles HL, Hemerly JP, Pauletti PM, Pandolfi JR, Araujo AR, Valentini SR, Young MC, Bolzani VS, Silva DH. Cytotoxic lignans from the stems of *Styrax camporum* (Styracaceae). *Nat Prod Res*, 2005; 19:319-323.

Timmers MA, Guerrero-Medina JL, Esposito D, Grace MH, Paredes-López O, García-Saucedo PA, Lila MA. Characterization of phenolic compounds and antioxidant and anti-inflammatory activities from Mamuyo (*Styrax ramirezii* Greenm.) fruit. *J Agric Food Chem*, 2015; 63:10459-10465.

Zhang YJ, Gan RY, Li S, Zhou Y, Li AN, Xu DP, Li HB. Antioxidant phytochemicals for the prevention and treatment of chronic diseases. *Molecules*, 2015; 20:21138-21156.

Yoshikawa K, Bando S, Arihara S, Matsumura E, Katayama S. A benzofuran glycoside and an acetylenic acid from the fungus *Laetiporus sulphureus* var. *miniatus*. *Chem Pharm Bull*, 2001; 49:327-329.

How to cite this article:

Silva TA, Polo EM, Henrique CY, Alves OJA, Nicoletta HD, Gimenez VMM, Araújo ARB, Tavares DC, Silva MLA, Cunha WR, Januário AH, Pauletti PM. *Styrax camporum* and *S. ferrugineus* fruits: norneolignans, antioxidant and cytotoxic activities. *J App Pharm Sci*, 2016; 6 (11): 075-080.